Page last updated: 2024-12-11
diffusomycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
diffusomycin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6438468 |
MeSH ID | M0209030 |
Synonyms (7)
Synonym |
---|
136360-48-0 |
(4z,6z,8e)-3-hydroxy-n-[(2e,4e,7r,9s)-6-hydroxy-9-[(5s,6r)-5-hydroxy-6,8-dimethyl-3,7-dioxo-2-oxa-8-azaspiro[3.4]octan-5-yl]-9-methoxy-7-methyl-nona-2,4-dienyl]-2,2,4-trimethyl-10-oxazol-5-yl-deca-4,6,8-trienamide |
3-hydroxy-n-[6-hydroxy-9-(8-hydroxy-5,7-dimethyl-1,6-dioxo-2-oxa-5-azaspiro[3.4]oct-8-yl)-9-methoxy-7-methyl-2,4-nonadienyl]-2,2,4-trimethyl-10-(5-oxazolyl)-4,6,8-decatrienamide |
diffusomycin |
oxazolomycin |
3-hydroxy-n-(6-hydroxy-9-(8-hydroxy-5,7-dimethyl-1,6-dioxo-2-oxa-5-azaspiro(3.4)oct-8-yl)-9-methoxy-7-methyl-2,4-nonadienyl)-2,2,4-trimethyl-10-(5-oxazolyl)-4,6,8-decatrienamide |
(4z,6z,8e)-3-hydroxy-n-[(2e,4e,7r,9s)-6-hydroxy-9-[(7r,8s)-8-hydroxy-5,7-dimethyl-3,6-dioxo-2-oxa-5-azaspiro[3.4]octan-8-yl]-9-methoxy-7-methylnona-2,4-dienyl]-2,2,4-trimethyl-10-(1,3-oxazol-5-yl)deca-4,6,8-trienamide |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (20)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 8 (40.00) | 29.6817 |
2010's | 6 (30.00) | 24.3611 |
2020's | 2 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.49
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.49) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |